Skip to main content

Publication, Part of

National Diabetes Audit (NDA) 2021-22 quarterly report for England, Clinical Commissioning Groups and GP practices

Audit, Survey, Other reports and statistics, Official statistics

Summary

This report provides provisional England, Clinical Commissioning Group (CCG) and GP practice level data for January to June 2021 (part of the NDA 2021-22 audit period). The worksheets include data for all CCGs and GP practices in England within the August 2021 extraction of NDA data (January 2021 to June 2021 data). These data are provisional and have been subject to fewer data quality and validation checks than data included in final NDA publications.

Data for Local Health Boards (LHB) in Wales and Specialist Diabetes Services are not included in this publication. Their 2021-22 data (for the full audit period January 2021 to March 2022) will be extracted as part of the final NDA 2021-22 collection and reported in the NDA 2021-22 short report publication, scheduled for late 2022.

Disclosure control has been applied to mitigate the risk of patient identification. Zeros are reported, and all numbers are rounded to the nearest 5, unless the number is 1 to 7, in which case it is rounded to ‘5’. This allows for more granular data to be made available, and also for data for all GP practices to be made available.

Please note that an issue has been identified with the source data from one GP system supplier whereby no records were submitted for a set of SNOMED codes relating to statin prescriptions, which are new for this audit period. This has resulted in the reported numerator counts, and associated percentages, for the completion of the following treatment targets being considerably lower than what is believed to be the true value: Primary Prevention - On Statins without CVD History, Secondary Prevention - On Statins with CVD History, Combined Prevention - On Statins, and All Three Treatment Targets NEW



Last edited: 8 December 2021 4:43 pm